ANTI COUNTERFEIT FROM COMMUNITY PERSPECTIVE -Estimates indicates 30% of drugs in Kenyan market are fake. -40 billion lost every year due to counterfeit.

Slides:



Advertisements
Similar presentations
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Advertisements

Promoting patient-centred healthcare around the world Advancing the fight against counterfeit medicines Ms. Regina Kamoga IAPO Board Member, Country Manager,
Why Not the Best? A High Performance Health System in Hawaii Hawaii Uninsured Project Fall Forum October 23, 2006 Anne Gauthier Senior Policy Director.
MeTa, Solwezi 27 August,2013.  A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs.
David Oyat Abang NAFOPHANU Uganda
Failure to Deliver: Violations of Women’s Human Rights in Kenyan Health Care Facilities FEBRUARY 4, RD AFRICA CONFERENCE ON SEXUAL HEALTH RIGHTS.
Antibiotic Policy in Ghana; the way forward
Inclusion of Adolescents with Disabilities: Towards an AIDS-Free Generation All In! Rosangela Berman Bieler Senior Adviser, Children with Disabilities,
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
The emergence of an Enforcement Agenda Intellectual Property Rights and Access to Essential Medicines: Challenges and Opportunities in Free Trade Agreement.
Dorcas Sithole Mental Health Department Ministry of Health & Child Welfare 1.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA. Presentation by: Dr. Joseph K. Yano B.Pharm (Nbi) L.L.B (Moi) Legal Officer Pharmacy and Poisons Board Ministry.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
1 HIV/AIDS Related Research Agenda Workshop Phnom Penh, Sunway Hotel March 28-29, 2007.
1 Stop Stock-outs! Access to Medicines for All! anti-counterfeiting initiatives and other access barriers Christa Cepuch OSI AEM Initiative – CS Role and.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
ACCESS TO MEDICINES - POLICY AND ISSUES
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.
Keep your promise to women and girls Violence against Women and Girls in National AIDS plans.
THE REPUBLIC OF UGANDA National AIDS Conference Presentation during the 4 th Uganda AIDS partnership Forum, Munyonyo, 31 st January 2006 By James Kaboggoza-Ssembatya,
HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.
Exploring financing options NATIONAL TB CONTROL OF VIETNAM.
Downloaded from Partnership for Implementation of workplace Programs Emmanuel Alhassan NACA ICASA, Abuja,
The Role of PLWHA in Universal Access to Care and Treatment by 2010 Presented by Christopher Dorsett Chair, CRN+
1/28/2016 Prevention Research and Natioanl Aids Plans Geneva 1 Prevention Research and National AIDS Plans June 2005 Geneva, Switzerland Prof. Roy.
Japan’s Perspective on Combating Counterfeiting and Piracy Third Global Congress on Combating Counterfeiting and Piracy Hisamitsu Arai January 30, 2007.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
Health Reform: An Overview Unit 4 Seminar. The Decision The opinions spanned 193 pages, upholding the individual insurance mandate while reflecting a.
CONSTRAINTS TO PRIMARY HEALTH CARE DELIVERY THE GOVERNMENT OBJECTIVES FOR DELIVERING PHC SERVICES To increase accessibility to quality health care services.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
SDG Action Plan: Congress of South African Trade Unions Matthew Parks COSATU Parliamentary Office.
Challenges and Constraints for TB Control in Kenya Dr. James Nyikal Director of Medical Services, Kenya.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
 The Work of Civil Society in the Field of HIV Prevention Brussels, 23 February 2011 The Work of European AIDS Treatment Group (EATG) 1.
Aids treatment on the field Experiences from CAMEROON Swiss AIDS platform Aidsfocus Bern, April 2004 Béata UMUBYEYI.
TB and the right to health Nelson Otwoma National Coordinator- NEPHAK.
Human Rights and Access to Medicines Sean Flynn AU, Washington College of Law Abuja, Nigeria, November 2008.
HIV Prevention, Treatment and Care in Prison Settings: Public Health and Human Rights Approach AIDS 2016 Conference Durban, South Africa 20 July 2016 Ehab.
Taxonomy of Strategies
MOVING FORWARD Enhanced ART Monitoring in Countries: Botswana
The Aviator Hotel – South Africa Uganda Harm Reduction Network (UHRN)
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
Health Technology Assessment
Expanding ARV treatment in developing countries: Issues and Prospects
HEALTH CARE POLICY.
The Debswana Anti Retroviral Therapy Programme
This is an archived document.
JEFFERSON CHAMBER OF COMMERCE HEALTHCARE CONFERENCE
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
The Right to Health and Access to Medicines
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Medicine in third world countries
Funding gaps to realize the Global Plan to End TB
Access to HIV/AIDS Medicines The 3x5 strategy
Fight Against Falsified medicines
South Africa: From ProTest to Nationwide Implementation
The STOP TB Strategy – 2009 VISION: A TB-free world
Steps in Implementing an Impact Evaluation
A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.
How can we make healthcare purchasing in Kenya more strategic?
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA
Presentation transcript:

ANTI COUNTERFEIT FROM COMMUNITY PERSPECTIVE -Estimates indicates 30% of drugs in Kenyan market are fake. -40 billion lost every year due to counterfeit.

ANTI –COUNTERFEIT AGENCY (ACA) Falls under the ministry of industrialization Charged with administering the recently enacted anti-counterfeit Act. They have powers to destroy fake goods imported into the country. They are charged with investigating and arresting people who trade in these goods.

ANTI-COUNTERFEIT COURT CASE IN KENYA On July 8 th people sued the government over the act sighting the following -The act infringes on the right of people to access essential medications. -The act denies life saving ARVs to about 300,000 people and an equivalent number on the waiting list. -The act confuses counterfeits with generics medicines.(not clear).

CONT/D -The act goes against the peoples right to life as enshrined in the Kenyan constitution. -The act is supposed to be implemented by KRA which was thought to have no capacity. The act recognizes intellectual property rights of other countries.

COURT RULING In April the court ruled barring the ACA from implementing the act until the issue is resolved- This means -The agency cannot interfere with importation and distribution of generic medicines in Kenya so far.

GENERIC MEDICINES Generic medicines are 90% cheaper and forms the bulk of all medicines in Kenya. They are accessible and affordable to the poor majority of Kenyans. They are not counterfeits. They are effective.

REALITY ABOUT MEDICINES IN THE COMMUNITY The cost of medicines cripples households budgets. Majority of the poor rural communities cannot afford the cost of life saving medicines No social insurance cover in place Essential medicines in government hospitals are not readily available-stock outs-prices goes up.

VULNERABILITY OF THE COMMUNITIES Lack of knowledge to differentiate what is fake and what legal. Poverty. No adequate information is given when dispensing medications. Counterfeits are present in most health care markets where people can be cheated. Low penalties on the offenders. Making the business to go on.

COUNTERFEIT TRADE CONTINUES DUE TO: Markets and distribution chain not regulated High cost of medicines Scarcity of basic essential medicines Weak regulatory controls Counterfeit trade is murder just like terrorism against public health.

CHALLENGES TO KNASP IF THE ACT WAS TO BE IMPLEMENTED DELIVERING ON UNIVERSAL ACCESS -Not possible to meet the national targets. -Legislation or policies should support the strategy. -More expensive treatment will be required when resistance develops.

CHALLENGES/IMPACT TO THE COMMUNITY Death is inevitable when life saving drugs are no longer available. Treatment failure Prevention programs fails completely More babies will be born hiv positive as PMTCT will no longer be effective.

RECOMENDATIONS Treatment should not only prolong life but improve its quality. Initiation of treatment should adhere with the current WHO guidelines. D4t(stavudine) Changed with less toxic drugs. Treatment monitoring to detect treatment failure early-quality laboratory tests. T.B. infection control policy.

CONT/D To protect patients and consumers give them appropriate information and education on the consequences of counterfeits. Ministries,NGOs and all other actors to participate in campaigns targeting consumers. Promotion and awareness of the problems of counterfeits through various channel Television.radios, posters etc.

CONT/D Only 15% of children in need of hiv/aids treatment are receiving-Policy (including testing for children).Let them be part of universal access. Government to honor Abuja declaration of funding to 15% of the national budget – Health. Treatment literacy to form part of comprehensive care services.

CONT/D The best strategy of prevention is to treat people. THANK YOU. END.